Leading the Way for Pediatric Behavioral Health
We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.
We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.
Now Available: Canvas Dx™(Rx only)
Developing Digital Diagnostic and Therapeutic Products for Behavioral Health
Providers
We are designing digital products that may enable providers to diagnose behavioral health conditions earlier, starting with autism.
Parents
We seek to support parents and caregivers
to act on early concerns about their child’s development.
Careers
Join our diverse team with opportunities spanning product, engineering, data science,
and clinical.
Recent Press Releases
Cognoa named one of Fierce Medtech’s “Fierce 15” Companies of 2021
Cognoa is designated as one of the most most promising private med tech companies in the industry.
Publications in Peer Reviewed Journals
FDA Breakthrough Designation Products
Cognoa has received Breakthrough Device Designation from the FDA for both its lead products, a digital diagnosis aid and therapeutic for autism.
Early Intervention Lasts a Lifetime
Autism diagnosis and intervention during the critical early neurodevelopmental period improves lifelong outcomes for children with autism.1-3 Early intervention within the neurodevelopmental window can yield significant improvements in behavioral, social, emotional, and cognitive functioning among individuals living with autism.¹
- Estes A, et al. J Am Acad Child Adolesc Psychiatry. 2015;54(7):580-587.
- Strain PS, Bovey EH. Topics in Early Childhood Special Education. 2011;31(3):133-154.
- Peters-Sheffer N, et al. Res Autism Spectr Disord. 2011;5(1):60-69.